Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda has licensed fruquintinib, HUTCHMED's oral VEGFR tyrosine kinase inhibitor, for $400 million upfront plus up to $730 million in milestones. Fruquintinib…
Japan's Takeda Pharmaceutical said on Monday it had agreed to pay up to $1.13 billion for worldwide ex-China rights to HUTCHMED's colorectal cancer drug…
The FDA approved fruquintinib (Fruzaqla, Takeda) for the treatment of adult patients with refractory metastatic colorectal cancer previously treated with…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Takeda acquired exclusive worldwide ex-China license to HUTCHMED's fruquintinib for $400M upfront and up to $730M in regulatory, development and commercial sales milestones plus royalties (total $1.13B). Phase 3 FRESCO-2 met its OS endpoint in refractory metastatic CRC. Deal closed March 14, 2023. The asset has since become a commercial success: FDA approval (Nov 8, 2023) under the brand FRUZAQLA was followed by European Commission approval (June 21, 2024), Japan approval (Sept 2024), and Health Canada authorization (2025). FRUZAQLA generated $290.6M in ex-China in-market sales in 2024 (2023 launch stub: $15.1M), triggering HUTCHMED's first $20M commercial milestone payment in Oct 2024 after sales surpassed $200M within a year of launch.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / HUTCHMED (China) Limited (this deal) | 2023 | $1.1B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2023 deals · Takeda Pharmaceutical Company Ltd. deals · Oncology deals